For example, the PARP1 gene has been proven to be an essential gene specific to mutated BRCA (i.e., synthetically lethal to mutated BRCA), and the use of the PARP1 inhibitor olaparib was approved for treating BRCA-mutated ovarian cancer [4]. This evidence concerns the gene PARP1 and ovarian carcinoma.